CLINICAL TRIALS PROFILE FOR CC-220

Clinical Trials for CC-220

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT01733875 ↗	2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects	Completed	Celgene	Phase 1	To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single oral dose of CC-220 and to explore the effect of food on the bioavailability of CC-220 in healthy subjects
NCT01733875 ↗	2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects	Completed	Celgene Corporation	Phase 1	To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single oral dose of CC-220 and to explore the effect of food on the bioavailability of CC-220 in healthy subjects
NCT02034773 ↗	3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule	Completed	Celgene Corporation	Phase 1	To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of CC-220 in healthy subjects and to evaluate the relative bioavailability of a formulated CC-220 capsule
NCT02185040 ↗	A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.	Completed	Celgene	Phase 2	The purpose of this study is to determine whether CC-220 is effective for the treatment of skin, joint and serological manifestations of systemic lupus erythematosus.
NCT02185040 ↗	A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.	Completed	Celgene Corporation	Phase 2	The purpose of this study is to determine whether CC-220 is effective for the treatment of skin, joint and serological manifestations of systemic lupus erythematosus.
NCT02192489 ↗	A Phase 2 Study With CC-220 in Skin Sarcoidosis	Withdrawn	Celgene	Phase 2	This study will evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of oral CC-220 in adult subjects with chronic cutaneous sarcoidosis.
NCT02192489 ↗	A Phase 2 Study With CC-220 in Skin Sarcoidosis	Withdrawn	Celgene Corporation	Phase 2	This study will evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of oral CC-220 in adult subjects with chronic cutaneous sarcoidosis.

Clinical Trial Conditions for CC-220

Condition Name

Condition Name
Intervention	Trials
Multiple Myeloma	10
Healthy Volunteers	4
Lymphoma, B-Cell	2
Systemic Lupus Erythematosus	1

Condition MeSH

Condition MeSH
Intervention	Trials
Multiple Myeloma	12
Neoplasms, Plasma Cell	12
Lymphoma	5
Lymphoma, B-Cell	3

Clinical Trial Locations for CC-220

Trials by Country

Trials by Country
Location	Trials
United States	153
Canada	21
China	17
Spain	13
Australia	12

Trials by US State

Trials by US State
Location	Trials
Texas	12
New York	10
Florida	10
Pennsylvania	8
Georgia	8

Clinical Trial Progress for CC-220

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 3	2
Phase 2	6
Phase 1/Phase 2	7

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Recruiting	11
Completed	8
Not yet recruiting	7

Clinical Trial Sponsors for CC-220

Sponsor Name

Sponsor Name
Sponsor	Trials
Celgene	17
Celgene Corporation	6
Bristol-Myers Squibb	5

Sponsor Type

Sponsor Type
Sponsor	Trials
Industry	34
Other	6
NIH	2